In the first interview of the series, Judd W. Moul, MD, provides an overview of the management of mHSPC and mCRPC including key considerations in the use of the androgen deprivation therapy leuprolide with or without novel hormone therapy or chemotherapy.
Philippe Spiess, MD, Moffitt Cancer Center, discusses the latest developments in the evolving treatment paradigm for patients with penile cancer.
Based on previously reported CheckMate-274 data, the FDA approved nivolumab for the adjuvant treatment of patients with urothelial carcinoma.
“We use a lot of clinical characteristics, but I’m hopeful we will start to go into more molecular typing and gene signatures,” says Tian Zhang, MD.
Joshua J. Meeks, MD, PhD, recaps several presentations on bladder cancer from the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana.
“We're doing probably one of the highest volume of HoLEP cases…in the United States,” says Nicole L. Miller, MD, FACS.
Ashley E. Ross, MD, PhD, recaps several presentations on prostate cancer from the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana.
Philippe Spiess, MD, MS, FACS, recaps several presentations from the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana.
“When you're talking about ‘impact,’ I don't think it gets any bigger than treating male infertility, because you're surgically treating the man, of course, but you're really treating the couple as a whole, and you're helping potentially create a new life,” says Justin Dubin, MD.
In the first video of the series, Jennifer A. Linehan, MD, provides an overview of LG-UTUC including risk factors, signs and symptoms, and diagnosis as well as factors to consider regarding disease progression, recurrence, and which patients might be candidates for resection.
Guru P. Sonpavde, MD, discusses the 2022 ASCO Annual Meeting abstract, “Real-world treatment patterns and clinical outcomes with first-line therapy in cisplatin-eligible and ineligible patients with advanced urothelial carcinoma.”
Phillip Kuo, MD, PhD, discusses the abstract, “[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy,” which was presented at the 2022 ASCO Annual Meeting.
“I think that there's certainly recognition that HoLEP is a procedure that can be self-taught and learned. But I think the learning curve is significantly shortened if you're mentored and certainly if you're fellowship trained,” says Nicole L. Miller, MD, FACS.
“Several years ago, we eliminated the high stakes component of our exam and made it into more of an educational process,” says David Joseph, MD.
In their study, Joshua Halpern, MD, and co-investigators examined the link between low testosterone and frailty in veterans undergoing cancer surgery.
Sumanta K. Pal, MD, highlights next steps now that the combination of cabozantinib and atezolizumab showed promising clinical activity in bladder cancer in the phase 1b COSMIC-021 trial.
Robert E. Brannigan, MD, discusses which men with infertility issues should receive genetic testing.
“What made [multichannel urodynamics] so important is you're able to diagnose things much better; you're able to have a much better understanding of what's actually going on,” says Howard B. Goldman, MD, FACS.
Pal highlights results from the phase 1b COSMIC-021 trial in which cabozantinib plus atezolizumab showed promising clinical activity in patients with urothelial carcinoma.
The ENZAMET study explored enzalutamide in patients with metastatic hormone-sensitive prostate cancer.
“For patients who are several years out from treatment for bladder cancer or kidney cancer, I don't think [the shortage is] going to have a clinical impact. For more acute settings, I have tried to rely a little bit more on MR urograms and ultrasound,” says Yair Lotan, MD.
Lead author Ian Davis, MBBS, PhD, discusses the results of the ENZAMET study update he shared during the 2022 ASCO Annual Meeting.
“I think immunotherapy in the neoadjuvant and also in the BCG-unresponsive setting are here to stay,” says Roger Li, MD.
Rao is an investigator on the ongoing phase 3 CASPAR trial exploring the AR pathway inhibitor enzalutamide combined with the PARP inhibitor rucaparib in patients with mCRPC.
"It's not perfect; you have to sort of retrain it, and there are some downsides to it. But it's the closest that we can get to, essentially, an artificial bladder," says Eila C. Skinner, MD.
“We found in ARCHES that in the men who developed radiographic progression while on ADT-enzalutamide [Xtandi], two thirds of these patients, when they had radiographic progression, did not meet PSA progression criteria, and one third didn't have any rise at all in their PSA,” says Andrew J. Armstrong, MD, MSc.
Based on the efficacy of the LITESPARK-001 study, the phase 3 LITESPARK-005 study of belzutifan has already been launched, says Eric Jonasch, MD.
“This analysis has a median follow-up of 41 months,” says Jonasch.
The new findings, “further support the use of adjuvant pembrolizumab after nephrectomy as a standard of care in patients with localized renal cell carcinoma at increased risk for recurrence,” says Toni K. Choueiri, MD.
Janet Kukreja, MD, discusses 5 studies in bladder cancer being presented at the 2022 ASCO Annual Meeting.
